ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
127.411,55
-0,27%
S&P 500
5.321,41
0,25%
US Dollar vs BRL
5,1233
0,00%
Bitcoin
69.757,50
-0,53%
Brent Oil
82,25
-0,24%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Aclarion Inc (ACON)

  7. Aclarion Inc (ACON) Notícias

ACON

Aclarion (ACON)

Aclarion Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:ACON
DataHoraFonteTítuloCódigoCompanhia
25/04/202410:14GlobeNewswire Inc.Aclarion’s Nociscan Solution to Play Key Role in Groundbreaking LIFEHAB Trial Evaluating the Diagnosis and Treatment of Chronic Low Back PainNASDAQ:ACONAclarion Inc
06/03/202418:09Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ACONAclarion Inc
04/03/202410:00GlobeNewswire Inc.Aclarion Announces Publication of Compelling Peer-Reviewed Data in International Journal of Spine Surgery Supporting Nociscan as a Gold Standard for Noninvasive Identification of Painful Lumbar DiscsNASDAQ:ACONAclarion Inc
27/02/202417:22GlobeNewswire Inc.Aclarion Announces Closing of $3.0 Million Public OfferingNASDAQ:ACONAclarion Inc
27/02/202416:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACONAclarion Inc
27/02/202412:46Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:ACONAclarion Inc
27/02/202402:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ACONAclarion Inc
26/02/202411:15GlobeNewswire Inc.Aclarion Announces Pricing of $3.0 Million Public OfferingNASDAQ:ACONAclarion Inc
23/02/202413:46Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:ACONAclarion Inc
05/02/202410:00GlobeNewswire Inc.Aclarion Announces Successful Financings; Plans to Launch CLARITY Trial and Provides Update on Next Steps of Alphatec Strategic PartnershipNASDAQ:ACONAclarion Inc
01/02/202419:16Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ACONAclarion Inc
22/01/202418:48Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:ACONAclarion Inc
22/01/202410:00GlobeNewswire Inc.Aclarion Expands Nociscan Access Into Phoenix With Key Opinion Leader Surgeon Advisor Juan Uribe, MDNASDAQ:ACONAclarion Inc
17/01/202410:00GlobeNewswire Inc.Aclarion Announces Updated Product Release That Expands MRI Scanner Access for Nociscan SolutionNASDAQ:ACONAclarion Inc
08/01/202410:00GlobeNewswire Inc.Aclarion and ATEC Execute Strategic Partnership Agreement to Advance Commercialization of NociscanNASDAQ:ACONAclarion Inc
02/01/202414:00GlobeNewswire Inc.Aclarion Announces Reverse Stock SplitNASDAQ:ACONAclarion Inc
29/12/202308:30Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ACONAclarion Inc
27/11/202310:00GlobeNewswire Inc.Aclarion Announces Key Commercial Milestone With Completion of 1,000 Nociscan ExamsNASDAQ:ACONAclarion Inc
13/11/202308:00Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ACONAclarion Inc
08/11/202310:00GlobeNewswire Inc.Aclarion Announces Achievement of Goal to Enroll 10 Leading Spine Surgery Key Opinion Leaders (KOLs) to Support Nociscan AdoptionNASDAQ:ACONAclarion Inc
06/11/202310:00GlobeNewswire Inc.Aclarion Expands Immediate Nociscan Access Into New York City With Tenth Key Opinion Leader Surgeon Advisor Addition Roger Hartl, MDNASDAQ:ACONAclarion Inc
01/11/202317:15Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:ACONAclarion Inc
01/11/202309:00GlobeNewswire Inc.Aclarion Presents at the NIH HEAL Initiative Fall MeetingNASDAQ:ACONAclarion Inc
25/10/202309:30GlobeNewswire Inc.Aclarion Announces Signing of Commercial Agreement With Porter Hospital, an AdventHealth facility, to Bring Nociscan Technology to DenverNASDAQ:ACONAclarion Inc
24/10/202309:45GlobeNewswire Inc.Aclarion Announces Nociscan® Cost-Effectiveness Poster Presented at 45th Annual SMDM MeetingNASDAQ:ACONAclarion Inc
23/10/202308:00GlobeNewswire Inc.Aclarion Announces Signing Strategic Partnership Letter of Intent With ATEC to Advance Commercialization of NociscanNASDAQ:ACONAclarion Inc
02/10/202309:00GlobeNewswire Inc.Aclarion Provides Updated Investor Presentation and Corporate UpdateNASDAQ:ACONAclarion Inc
25/08/202317:10GlobeNewswire Inc.Aclarion, Inc. Announces Filing of Delayed 10-Q Quarterly ReportNASDAQ:ACONAclarion Inc
25/08/202314:04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ACONAclarion Inc
14/08/202317:27Edgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSBNASDAQ:ACONAclarion Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:ACON

Seu Histórico Recente

BIT
UV8CSH
UniCredit Bank
BINA
ADABRL
Cardano
EU
S429S
S429S
USOTC
ATUUF
Tenaz Energy (PK)
EU
5026D
5026D
BIT
F31100
Vontobel Financial Produ...
COIN
GLMUST
Golem Network Token
LSE
0A6M
Nabors Industries
NYSE
AVK
Advent Convertible and I...
NASDAQ
ABALZXX
Hsbc Bank Usa Na Capped ...
BIT
F18552
Vontobel Financial Produ...
TSXV
LDM
Lago Dourado Minerals Ltd.
COIN
B24GBP
UNSW3
XYZETH
XYZ Governance Token
NASDAQ
FMFBKX
Water Utility And Infras...
BIT
S29066
Societe Generale Effekten
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados